What is the clinical evidence from this study?

Study design: Observational. Population: Abnormalities of primary haemostasis. Intervention: PFA-100 device. Primary outcome: Closure time.

What question did this study set out to answer?

This research aims to evaluate the efficacy of the PFA-100 device in assessing primary haemostasis and identify abnormalities in platelet function.

January 1, 1999Blood Coagulation & Fibrinolysis

Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasis

View Full Paper

Ask AI

Bookmark

Key result

The PFA-100 device reliably detected primary haemostasis abnormalities, showing infinitely prolonged closure times (>200 s) in patients with von Willebrand's disease and Glanzmann's thrombasthenia.

Why the study?

Does the PFA-100 device reliably detect abnormalities of primary haemostasis in patients with known platelet or coagulation factor defects?

Key Points

This research aims to evaluate the efficacy of the PFA-100 device in assessing primary haemostasis and identify abnormalities in platelet function.
Utilized the PFA-100 device to measure closure times in patients with different hematological conditions.
Analyzed 4 patients with type 3 von Willebrand's disease, 6 with Glanzmann's thrombasthenia, and 2 with Bernard Soulier syndrome.
Evaluated the impact of aspirin on closure times in normal subjects and patients.
Patients with type 3 von Willebrand's disease had infinitely prolonged closure times (> 200 s).
Patients with Glanzmann's thrombasthenia and Bernard Soulier syndrome also exhibited significantly prolonged closure times (> 200 s).
Aspirin ingestion led to significant prolongation of closure times for the epinephrine cartridge, whereas ADP results varied.

Study Design

Type

Observational

Structured PICO

Does the PFA-100 device reliably detect abnormalities of primary haemostasis in patients with known platelet or coagulation factor defects?

Population

Patients with various primary haemostasis abnormalities and normal subjects evaluated using the PFA-100 device.

Exposure

In-vitro testing of platelet function using the PFA-100 device with collagen and either epinephrine or ADP cartridges.

Outcome

Closure time (time taken for platelets to seal a 150 microm aperture).surrogate

The PFA-100 device offers a reliable, reproducible, and rapid in vitro assessment of high-shear platelet function that is highly dependent on von Willebrand factor and glycoproteins Ib and IIb/IIIa.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support PFA-100 in specialized hemostasis evaluation; leaves open prospective validation in broader populations.

Cite This Study

Harrison et al. (1999) conducted an observational in Abnormalities of primary haemostasis. PFA-100 device was evaluated on Closure time. The PFA-100 device reliably detected primary haemostasis abnormalities, showing infinitely prolonged closure times (>200 s) in patients with von Willebrand's disease and Glanzmann's thrombasthenia.

synapsesocial.com/papers/6a6ac16a547974b2dbf41eff https://doi.org/10.1097/00001721-199901000-00004

View Full Paper

Ask AI

Bookmark

Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasis

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasis

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider